Background: Previous studies identified differences by race in the distribution of medical problems associated with morbid obesity. Whether or not outcomes after LRYGB also vary by race is unknown. Objective: To identify racial variations in weight loss and resolution of obesity co-morbidities after LRYGB. Methods: Data from 83,059 BOLD database LRYGB patients was analyzed retrospectively in five groups: African-American (n=9,055), Caucasian (n=63,352), Hispanic (n=6,893), Asian (n=198), and Other (n=3,561). Results: Weight and BMI were higher in African-Americans versus Caucasians, Hispanics, Other (12 months, p<0.0001). Hypertension persisted increased among African-Americans versus Caucasians, Hispanics, Other through 24 months (p<0.01). Caucasian cholelithiasis (18 months, p<0.05), abdominal panniculitis (12 months, p<0.01,) and depression (24 months, p<0.05) continued higher than other races. GERD was highest in African-Americans and Caucasians. Dyslipidemia affected Caucasians, African-Americans, and Other most (12 months, p<0.05). Hispanic depression was lowest (24 months, p<0.05). Other had highest stress urinary incontinence (12 months, p<0.05). Racial differences in diabetes, liver disease, obstructive sleep apnea, obesity hypoventilation syndrome, gout, back and musculoskeletal pain, leg edema, alcohol use, and non-depression psychological issues were not significant beyond 6 months. Resolution of angina, CHF, pulmonary hypertension, and polycystic ovarian disease did not vary by race. Conclusions: LRYGB improves obesity weight and co-morbidity outcomes overall, but long-term treatment effects vary by race. African-American weight and hypertension, and African-American/Caucasian GERD, and dyslipidemia resolve least. Caucasian abdominal issues and depression dominate. Racial variations in many obesity co-morbidities disappear by 12 months post-operatively.